Journal
AMERICAN JOURNAL OF NEURORADIOLOGY
Volume 34, Issue 1, Pages 62-67Publisher
AMER SOC NEURORADIOLOGY
DOI: 10.3174/ajnr.A3148
Keywords
-
Funding
- Physician Services Incorporated Foundation
- Multiple Sclerosis Scientific Research Foundation
- National Institutes of Health
- Northwestern University
- Merck-Serono
- Teva
- Biogen
- Biogen Canada
- Serono Canada
- Teva Neurosciences
- Schering
- BioMS
- Sanofi-Aventis
- Allergan
Ask authors/readers for more resources
BACKGROUND AND PURPOSE: Cognitive impairment is a common, disabling symptom of MS. We investigated the impact of cerebral perfusion and brain and lesion volumetry on cognitive performance in 45 patients with SPMS by using MR imaging. MATERIALS AND METHODS: Cognition was assessed by using a standard battery, the Minimal Assessment of Cognitive Function in Multiple Sclerosis. qCBF and qCBV maps were analyzed by using SPM and PLS. SPM was also used to conduct the GM, WM, and WML volumetric analyses. RESULTS: Both SPM and PLS demonstrated significantly reduced qCBV in the superior medial frontal cortex of impaired patients. PLS also revealed significantly lower qCBV in the bilateral thalami and caudate nuclei of impaired patients and identified a pattern of significantly attenuated qCBF similar to that of qCBV. Performance on the Symbol Digit Modalities Test, which assesses information-processing speed, correlated most strongly overall with cerebral perfusion. Focal (ie, voxelwise) analyses of GM, WM, and WML volume revealed no significant differences between patients with and without cognitive impairment, though global GM volume was significantly decreased and global WML volume was significantly increased in impaired patients. CONCLUSIONS: These results suggest that cognitively impaired patients with SPMS exhibit robust perfusion deficits in cortical and subcortical GM and impaired processing speed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available